Shareholders of GI Dynamics Inc (ASX: GID) have watched helplessly as their shares have plummeted recently following an unfavourable announcement regarding its key product, EndoBarrier. The stock has crashed 6.3% today, giving it a total loss of 53% over the last six days.
Source: Yahoo! Finance
Last week, the junior medical device maker emerged from a trading halt which had been requested pending a “material announcement” regarding its business. Unfortunately, it was later confirmed that the US Food and Drug Administration (FDA) had put a hold on enrolment in the company’s ongoing clinical trial of EndoBarrier in the US, requesting further information regarding its risk/benefit profile. An unexpectedly high number of patients had become ill during the trial.
While the setback is certainly being felt by shareholders, investors would have been well aware of the high level of risk involved in biotechnology investments. While some, including Sirtex Medical Limited (ASX: SRX) and CSL Limited (ASX: CSL) have become successful over the years, countless others have resulted in terrible investor losses.
Our experts here at The Motley Fool Australia have just released a fantastic report, detailing 5 dirt cheap shares that you can buy in 2020.
One stock is an Australian internet darling with a rock solid reputation and an exciting new business line that promises years (or even decades) of growth… while trading at an ultra-low price…
Another is a diversified conglomerate trading over 40% off it's high, all while offering a fully franked dividend yield over 3%...
Plus 3 more cheap bets that could position you to profit over the next 12 months!
See for yourself now. Simply click here or the link below to scoop up your FREE copy and discover all 5 shares. But you will want to hurry – this free report is available for a brief time only.
Motley Fool contributor Ryan Newman does not own shares in any of the companies mentioned. You can follow Ryan on Twitter @ASXvalueinvest.